Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174798 · ClinicalTrials.gov registry record · Phase 2
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT00174798 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 118 participants.
The verdict
NCT00174798, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of SSR240600C versus placebo on clinical and cystometric parameters in patients with OAB and UUI.
Interventions
- DRUG Placebo
- DRUG Tolterodine
- DRUG SSR240600C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174798
The ClinicalTrials.gov registry entry for NCT00174798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00174798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174798 about?
NCT00174798 is a clinical study titled "MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.". To evaluate the safety and efficacy of SSR240600C versus placebo on clinical and cystometric parameters in patients with OAB and UUI.
What is the current status of trial NCT00174798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2005-05. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00174798?
The interventions under investigation include: Placebo (DRUG), Tolterodine (DRUG), SSR240600C (DRUG).
Who is sponsoring clinical trial NCT00174798?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.